The healthcare supply chain in Japan, as in all major markets, consists of biopharmaceutical manufacturers selling to wholesalers who in turn sell to hospitals, clinics, and pharmacies, where the drugs are finally dispensed to patients. Each party ideally contributes value…
COLUMN
Pricing Reform in Japan - How Manufacturers Can Ensure Fair Compensation for Value and Innovation
Last month, when discussing how life science manufacturers should react to the evolving pricing environment in Japan, I wrote about how manufacturers should align with stakeholders in government and the medical community on fair compensation for innovative, value creating, biopharmaceutical…
To read the full story
COLUMN
- Rewarding Value and Innovation and Ensuring Financial Viability of the Biopharmaceutical Supply Chain in Japan
March 16, 2023
- Why Market Mapping Is Critical to Your Organization
February 24, 2023
- When It Comes to Recruitment, Time Is Money. Have a Plan!
January 31, 2023
- Cell Therapy in Japan: A Potentially Attractive Market at a Turning Point Facing Challenges
December 16, 2022
- How to Succeed in Bad Times and Good
December 9, 2022
The health ministry’s key expert panel on February 15 agreed on the need to consolidate the Japanese generic sector to…
“Balance” seems to be the keyword for the next drug pricing reform in FY2024. Japan now appears ready to seek a better balance between evaluating innovative medicines and taking tough measures against companies dependent on long-listed products (LLPs) and generic…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…